EA201690492A1 - Проникающие в клетку конъюгаты и способы их применения - Google Patents
Проникающие в клетку конъюгаты и способы их примененияInfo
- Publication number
- EA201690492A1 EA201690492A1 EA201690492A EA201690492A EA201690492A1 EA 201690492 A1 EA201690492 A1 EA 201690492A1 EA 201690492 A EA201690492 A EA 201690492A EA 201690492 A EA201690492 A EA 201690492A EA 201690492 A1 EA201690492 A1 EA 201690492A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugates
- thiophosphate
- cellulating
- methods
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Abstract
В настоящем документе предложены приникающие в клетку конъюгаты. Конъюгаты содержат не проникающий в клетку белок, присоединенный к тиофосфатной нуклеиновой кислоте или остову тиофосфатного полимера, при этом тиофосфатная нуклеиновая кислота или остов тиофосфатного полимера повышают внутриклеточную доставку не проникающего в клетку белка. Также предложены композиции и наборы, содержащие конъюгаты.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361871729P | 2013-08-29 | 2013-08-29 | |
US201461939993P | 2014-02-14 | 2014-02-14 | |
PCT/US2014/053549 WO2015031837A1 (en) | 2013-08-29 | 2014-08-29 | Cell penetrating conjugates and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201690492A1 true EA201690492A1 (ru) | 2016-08-31 |
Family
ID=52587396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690492A EA201690492A1 (ru) | 2013-08-29 | 2014-08-29 | Проникающие в клетку конъюгаты и способы их применения |
Country Status (13)
Country | Link |
---|---|
US (2) | US10967070B2 (ru) |
EP (1) | EP3038639B1 (ru) |
JP (3) | JP6736464B2 (ru) |
KR (2) | KR102522346B1 (ru) |
CN (2) | CN111437395A (ru) |
AU (3) | AU2014312031A1 (ru) |
CA (1) | CA2922698C (ru) |
EA (1) | EA201690492A1 (ru) |
IL (1) | IL244296A0 (ru) |
MX (2) | MX2016002643A (ru) |
PH (1) | PH12016500395A1 (ru) |
SG (1) | SG11201601443PA (ru) |
WO (1) | WO2015031837A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2017116710A (ru) | 2014-10-23 | 2018-11-23 | Сингх Биотекнолоджи, Ллк | Однодоменные антитела, направленные против внутриклеточных антигенов |
US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
SG11201705413WA (en) * | 2015-01-16 | 2017-08-30 | Hope City | Cell penetrating antibodies |
TW201718024A (zh) * | 2015-08-06 | 2017-06-01 | 世代好公司 | 治療性細胞內化結合物 |
EP3331543A4 (en) * | 2015-08-06 | 2019-03-20 | City of Hope | CONJUGATES OF CELL PENETRATION FORMED OF PROTEIN AND ANTIBODIES AND METHODS OF USE |
CN108473574A (zh) * | 2015-10-20 | 2018-08-31 | 索伦托治疗有限公司 | 细胞内递送化合物 |
TWI746473B (zh) | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
TW201733621A (zh) * | 2015-12-10 | 2017-10-01 | 世代好公司 | 細胞穿透性之花青耦合抗體 |
KR20180059091A (ko) | 2016-11-25 | 2018-06-04 | 김정수 | 소비자 패션선호도 기반의 가상 피팅 방법, 그 시스템 및 시스템의 작동을 제어하기 위한 제어방법 |
EP3565601A2 (en) * | 2017-01-04 | 2019-11-13 | Sorrento Therapeutics | Cell internalizing compounds |
CN110770345A (zh) | 2017-04-14 | 2020-02-07 | 托尔奈公司 | 免疫调节多核苷酸、抗体缀合物及其使用方法 |
US11607457B2 (en) * | 2017-07-13 | 2023-03-21 | City Of Hope | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same |
EP3651807B1 (en) * | 2017-07-13 | 2023-11-01 | City of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
JP7130274B2 (ja) | 2017-12-22 | 2022-09-05 | ロフィバイオ インコーポレイテッド | 細胞内浸透能を有する抗stat3二重特異性抗体およびこれを含む薬学的組成物 |
KR20190076354A (ko) * | 2017-12-22 | 2019-07-02 | 주식회사 로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물 |
EP3805400A4 (en) | 2018-06-04 | 2022-06-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule showing changed half-life in cytoplasm |
US20220125891A1 (en) | 2018-06-06 | 2022-04-28 | Osaka University | Method for treating and/or preventing regnase-1-related disease |
WO2021237160A2 (en) * | 2020-05-22 | 2021-11-25 | City Of Hope | Phosphorothioate nucleic acid conjugates including dna editing enzymes |
US20230277612A1 (en) * | 2020-06-24 | 2023-09-07 | Sapreme Technologies B.V. | Saponin derivatives for use in medicine |
US20240115726A1 (en) * | 2020-06-24 | 2024-04-11 | Sapreme Technologies B.V. | Hydrazone-based saponin derivatives |
WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
WO2024129459A1 (en) | 2022-12-16 | 2024-06-20 | University Of Rochester | Repairmen! of barrier dysfunction in esophagus |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
KR20030097604A (ko) | 1992-07-13 | 2003-12-31 | 유카리언, 인코포레이티드 | 세포의 세포내 구획으로 지질화된 면역글로불린을전달하기 위한 조성물, 지질화된 단백질 및 지질화된 항체 |
PT651805E (pt) | 1992-07-17 | 2007-02-28 | Dana Farber Cancer Inst Inc | Método de ligação intracelular de moléculas-alvo |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
WO1995002422A1 (en) | 1993-07-12 | 1995-01-26 | Weltman Joel K | Method for conjugating nucleotides and nucleosides to disulfide-, maleimide-, and thiol-containing compounds |
AU1925195A (en) | 1994-02-22 | 1995-09-04 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
WO1998008859A1 (en) * | 1996-08-27 | 1998-03-05 | University Of Utah Research Foundation | Bioconjugates and delivery of bioactive agents |
WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
US6903077B1 (en) | 1999-01-04 | 2005-06-07 | University Of Vermont And State Agricultural College | Methods and products for delivering nucleic acids |
DE60040755D1 (de) | 1999-12-01 | 2008-12-18 | Novartis Vaccines & Diagnostic | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
US20040052762A1 (en) * | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
US20030158109A1 (en) | 2000-11-13 | 2003-08-21 | Klaus Giese | Metastatic breast and colon cancer regulated genes |
CA2464472C (en) | 2001-10-22 | 2014-01-07 | The Scripps Research Institute | Antibody targeting compounds |
US20050042632A1 (en) | 2002-02-13 | 2005-02-24 | Sirna Therapeutics, Inc. | Antibodies having specificity for nucleic acids |
US20040147027A1 (en) * | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
US20060222657A1 (en) | 2003-06-20 | 2006-10-05 | Dowdy Steven F | Polypeptide transduction and fusogenic peptides |
WO2005024033A2 (en) * | 2003-09-11 | 2005-03-17 | Universitätsklinikum Schleswig-Holstein Campus Lübeck | Nucleotide sequences promoting the trans-membrane transport of nucleic acids |
WO2005082935A1 (en) | 2004-02-26 | 2005-09-09 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Stamp modulation of glucocorticoid-responsive gene expression |
US7714119B2 (en) | 2004-07-13 | 2010-05-11 | Biosante Pharmaceuticals, Inc. | AAV vector compositions and methods for enhanced expression of immunoglobulins using the same |
CA2633063A1 (en) * | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids intocells |
US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
PL2446904T3 (pl) * | 2006-05-30 | 2015-10-30 | Genentech Inc | Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania |
US20090093425A1 (en) * | 2006-07-12 | 2009-04-09 | The Regents Of The University Of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
WO2009008725A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
US20110129421A1 (en) | 2007-07-17 | 2011-06-02 | The General Hospital Corporation | Matrix metalloprotease targeting nucleic acids |
CN102317303A (zh) * | 2007-07-31 | 2012-01-11 | 约翰·霍普金斯大学 | 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物 |
US20110218334A1 (en) * | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
JP5635512B2 (ja) * | 2008-09-16 | 2014-12-03 | カリエム・アーメド | 遺伝子調節化合物の改良された送達のための化学的に修飾された細胞透過性ペプチド |
US20100190691A1 (en) * | 2009-01-27 | 2010-07-29 | Trojan Technologies, Ltd | Delivery of nucleic acids using cell-penetrating peptides |
DK3903829T3 (da) | 2009-02-13 | 2023-06-26 | Immunomedics Inc | Immunkonjugater med en intracellulær spaltelig binding |
US8552167B2 (en) * | 2009-10-20 | 2013-10-08 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing |
NZ586074A (en) * | 2010-06-10 | 2013-07-26 | Auckland Uniservices Ltd | LCLRP peptides, constructs and uses thereof |
US20120122795A1 (en) | 2010-08-09 | 2012-05-17 | University Of Southern California | Accelerated extension of axons |
US9045750B2 (en) | 2011-03-18 | 2015-06-02 | Yuelong Ma | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 |
JP6178785B2 (ja) * | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
DK2751270T3 (en) | 2011-08-29 | 2018-10-29 | Ionis Pharmaceuticals Inc | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE |
-
2014
- 2014-08-29 EA EA201690492A patent/EA201690492A1/ru unknown
- 2014-08-29 CA CA2922698A patent/CA2922698C/en active Active
- 2014-08-29 JP JP2016537916A patent/JP6736464B2/ja active Active
- 2014-08-29 CN CN202010254165.7A patent/CN111437395A/zh active Pending
- 2014-08-29 CN CN201480055531.9A patent/CN105658230B/zh active Active
- 2014-08-29 WO PCT/US2014/053549 patent/WO2015031837A1/en active Application Filing
- 2014-08-29 SG SG11201601443PA patent/SG11201601443PA/en unknown
- 2014-08-29 EP EP14839093.3A patent/EP3038639B1/en active Active
- 2014-08-29 KR KR1020167008310A patent/KR102522346B1/ko active IP Right Grant
- 2014-08-29 KR KR1020217031968A patent/KR20210123433A/ko not_active Application Discontinuation
- 2014-08-29 MX MX2016002643A patent/MX2016002643A/es unknown
- 2014-08-29 AU AU2014312031A patent/AU2014312031A1/en not_active Abandoned
-
2016
- 2016-02-25 IL IL244296A patent/IL244296A0/en unknown
- 2016-02-29 PH PH12016500395A patent/PH12016500395A1/en unknown
- 2016-02-29 MX MX2021009190A patent/MX2021009190A/es unknown
- 2016-02-29 US US15/056,777 patent/US10967070B2/en active Active
-
2020
- 2020-03-09 AU AU2020201725A patent/AU2020201725B2/en active Active
- 2020-07-14 JP JP2020120404A patent/JP7053730B2/ja active Active
-
2021
- 2021-02-24 US US17/184,237 patent/US20210330804A1/en active Pending
-
2022
- 2022-03-31 JP JP2022059465A patent/JP2022091932A/ja active Pending
- 2022-07-27 AU AU2022209292A patent/AU2022209292A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2016002643A (es) | 2016-10-04 |
WO2015031837A1 (en) | 2015-03-05 |
EP3038639B1 (en) | 2023-11-15 |
JP2022091932A (ja) | 2022-06-21 |
JP7053730B2 (ja) | 2022-04-12 |
EP3038639A4 (en) | 2017-04-26 |
KR20210123433A (ko) | 2021-10-13 |
IL244296A0 (en) | 2016-04-21 |
US20210330804A1 (en) | 2021-10-28 |
EP3038639A1 (en) | 2016-07-06 |
JP2016531916A (ja) | 2016-10-13 |
US20160317671A1 (en) | 2016-11-03 |
MX2021009190A (es) | 2021-09-08 |
AU2020201725B2 (en) | 2022-04-28 |
CN105658230B (zh) | 2020-04-21 |
JP6736464B2 (ja) | 2020-08-05 |
JP2020180155A (ja) | 2020-11-05 |
CN111437395A (zh) | 2020-07-24 |
CN105658230A (zh) | 2016-06-08 |
AU2014312031A1 (en) | 2016-03-24 |
KR102522346B1 (ko) | 2023-04-17 |
SG11201601443PA (en) | 2016-03-30 |
CA2922698A1 (en) | 2015-03-05 |
CA2922698C (en) | 2023-01-03 |
US10967070B2 (en) | 2021-04-06 |
PH12016500395A1 (en) | 2016-05-16 |
AU2020201725A1 (en) | 2020-04-09 |
KR20160050051A (ko) | 2016-05-10 |
AU2022209292A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690492A1 (ru) | Проникающие в клетку конъюгаты и способы их применения | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
EA201991715A1 (ru) | Композиции, содержащие антитело к pdl1 | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CO7151531A2 (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
EA201590171A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
MX2021011584A (es) | Anticuerpos que penetran en celulas. | |
EA201690461A1 (ru) | Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
BR112015023752A2 (pt) | complexos multiespecificos monovalentes e multivalentes e seus usos | |
UY34885A (es) | Proteínas de unión anti-mesotelina | |
EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
EA201391298A1 (ru) | Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201590172A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
EA201690613A1 (ru) | Улучшенные составы на основе аденовирусов | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
UY34582A (es) | Anticuerpos anti-cxcr3 |